xCT, not just an amino-acid transporter: a multi-functional regulator of microbial infection and associated diseases by Lu Dai et al.
MINI REVIEW ARTICLE
published: 19 February 2015
doi: 10.3389/fmicb.2015.00120
xCT, not just an amino-acid transporter: a multi-functional
regulator of microbial infection and associated diseases
Lu Dai1,2, Mairi C. Noverr3, Chris Parsons2, Johnan A. R. Kaleeba4* and Zhiqiang Qin1,5*
1 Research Center for Translational Medicine and Key Laboratory of Arrhythmias of the Ministry of Education of China, East Hospital, Tongji University School of
Medicine, Shanghai, China
2 Department of Medicine, Louisiana State University Health Sciences Center, Louisiana Cancer Research Center, New Orleans, LA, USA
3 Department of Oral and Craniofacial Biology, Louisiana State University Health Sciences Center, Louisiana Cancer Research Center, New Orleans, LA, USA
4 Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA




University of Athens, Greece
Reviewed by:
Paras Jain, Albert Einstein College
of Medicine, USA
Aikaterini Pistiki, University General
Hospital ATTIKO, Greece
*Correspondence:
Johnan A. R. Kaleeba, Department
of Microbiology and Immunology,
Uniformed Services University of
the Health Sciences, 4301 Jones
Bridge Road, Bethesda, MD 20814,
USA
e-mail: kaleebajar@gmail.com;
Zhiqiang Qin, Department of
Microbiology, Immunology, and
Parasitology, Louisiana State
University Health Sciences Center,
Louisiana Cancer Research Center,
Room 743, 1700 Tulane Avenue,
New Orleans, LA 70112, USA
e-mail: zqin@lsuhsc.edu
Expression of xCT, a component of the xc− amino-acid transporter, is essential for the
uptake of cystine required for intracellular glutathione (GSH) synthesis and maintenance
of the intracellular redox balance. Therefore, xCT plays an important role not only in the
survival of somatic and immune cells, but also in other aspects of tumorigenesis, including
the growth and malignant progression of cancer cells, resistance to anticancer drugs, and
protection of normal cells against oxidative damage induced by carcinogens. xCT also
functions as a factor required for infection by Kaposi’s sarcoma-associated herpesvirus
(KSHV), the causative agent of Kaposi’s sarcoma (KS) and other lymphoproliferative
diseases associated with HIV/AIDS. In spite of these advances, our understanding of
the role of xCT in the pathogenesis of infectious diseases is still limited. Therefore, this
review will summarize recent findings about the functions of xCT in diseases associated
with microbial (bacterial or viral) infections, in particular KSHV-associated malignancies.
We will also discuss the remaining questions, future directions, as well as evidence that
supports the potential benefits of exploring system xc− as a target for prevention and
clinical management of microbial diseases and cancer.
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BACKGROUND
The xc− amino-acid transporter, consisting of xCT (also
named as SLC7A11) and its chaperone CD98, functions as
a Na+-independent electroneutral exchange system for cys-
tine/glutamate (Bannai and Kitamura, 1980). Expression of xCT
on the cell membrane is essential for the uptake of cystine required
for synthesis of intracellular glutathione (GSH), an anti-oxidant
that plays an important role in maintaining the intracellular
redox balance (Bannai, 1986; Patel et al., 2004). For most cancer
cells, the uptake of cystine/cysteine from the microenvironment
is crucial for growth and viability (Lo et al., 2008). Therefore,
xCT is highly expressed by a variety of malignant tumors such as
lymphoma, glioma, breast carcinoma, and prostate cancer (Gout
et al., 2001; Narang et al., 2003; Chung et al., 2005; Doxsee
et al., 2007). xCT is also involved in other important cellular
functions within cancer cells, such as chemoresistance (Okuno
et al., 2003; Huang et al., 2005) and autophagy (Guo et al., 2011).
Interestingly, xCT-deficient mice display impaired survival of acti-
vated macrophages at the inflammatory site, which subsequently
enhances chemically induced tumorigenesis (Nabeyama et al.,
2010). In addition, xCT has been associated with some central
nervous system (CNS) and eye diseases, such as cerebral ischemia
(stroke), trauma, Alzheimer’s disease and retinopathy (Choi,
1987; Bridges et al., 2004; Nagasawa et al., 2005; Qin et al., 2006).
Interestingly, we and others recently reported the functional
contributions of xCT to the pathogenesis of Kaposi’s sarcoma-
associated herpesvirus (KSHV; Kaleeba and Berger, 2006a,b; Qin
et al., 2010b, 2013; Dai et al., 2014a), a principal causative agent
of several cancers arising in patients with compromised immune
systems (Chang et al., 1994). In light of the emerging pleiotropic
functions of xCT, the goal of this review is to summarize recent
findings about the role of xCT in microbial infection and associ-
ated diseases (particularly virus-associated malignancies), and to
discuss potential future directions for research in this particular
field.
xCT AND KSHV PATHOGENESIS
xCT AS A CELLULAR RECEPTOR FOR KSHV ENTRY
Like other well-studied human herpesviruses, KSHV is presumed
to enter cells by direct fusion with the target cell membrane as
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the predominant mode of infection (Dezube et al., 2002; Pertel,
2002; Kaleeba and Berger, 2006a; Longnecker and Neipel, 2007),
although endocytosis and other receptor-independent mecha-
nisms of entry have also been described (Akula et al., 2003;
Rappocciolo et al., 2008; Greene and Gao, 2009; Garrigues et al.,
2014). Using a functional complementary DNA selection assay, we
recently identified xCT as an important component of a multi-
molecular complex that mediates KSHV entry by direct fusion
with the target cell membrane (Kaleeba and Berger, 2006b).
The KSHV receptor complex consists of xCT, CD98, and other
“outside-in” signaling molecules such as integrins, suggesting that
the virus also exploits pre-existing signaling pathways to initiate
events that promote virion entry into a variety of cell types.
Depending on the cell type, the initial stages of KSHV infection
involve target cell recognition through temporal interactions with
attachment factors (heparan sulfate and DC-SIGN) or signaling
molecules such as integrins (αvβ3, α3β1, and αvβ5); in some
cases, these initial steps may be sufficient to mediate virion
uptake, or they may be followed by recruitment of the CD98/xCT
complex that then mediates viral glycoprotein-mediated fusion of
the viral and target cell membranes (Veettil et al., 2008, 2014;
Hahn et al., 2009). While these discoveries have advanced our
understanding of the early events in the infectious process of
KSHV, several questions remain. For example, although recent
studies have demonstrated that KSHV can infect some B cell
subsets or cell-lines (Rappocciolo et al., 2008; Hassman et al.,
2011; Myoung and Ganem, 2011; Dollery et al., 2014), we found
that most monocytic and other immortalized lymphoblastoid
cell lines did not express detectable levels of xCT mRNA and
are generally refractory to KSHV infection. We also failed to
detect xCT mRNA in human CD19+ primary B cells isolated
from fresh peripheral blood mononuclear cells (PBMCs), which is
paradoxical given that the virus is etiologically linked to two B cell
lymphoproliferative disorders, namely multicentric Castleman’s
disease (MCD) and primary effusion lymphoma (PEL; Cesarman
et al., 1995; Soulier et al., 1995). Remarkably, ectopic expression
of recombinant xCT does not cure the poor target susceptibility
of B cell lines to KSHV, whereas over-expression of xCT in K562
cells and other cells that express α3, β1, αv, or β3 integrin subunits
can render these cells more susceptible to KSHV, suggesting that
the receptor function of xCT is more demonstrably robust in
adherent and other cells that also express the relevant integrin
co-receptor complexes that provide the requisite supporting role
for efficient virion adsorption and signaling prior to virion entry.
Interestingly, a recent study found that activated blood and tonsil-
lar B cells can be productively infected with KSHV, which can be
blocked by the pretreatment of the cells with antibody specific for
DC-SIGN or with the selective DC-SIGN inhibitor, mannan, but
not antibody specific for xCT (Rappocciolo et al., 2008). We also
recently demonstrated that heparan sulfate (HS), not xCT, may be
required for KSHV infection of human primary oral fibroblasts
(Dai et al., 2014b). Together, these findings suggest that the recep-
tor function of xCT may be cell-context dependent and is presum-
ably determined by physiologic triggers of receptor expression
within the target site, as well as the relative surface expression of
various cell-type specific cofactors and other accessory molecules
that must be recruited to the virion attachment site.
xCT AND SURVIVAL OF KSHV-INFECTED CELLS
The biological relevance of xCT in KSHV pathogenesis goes
beyond its function as a virus receptor. As mentioned above,
xCT naturally functions as a transporter for extracellular cys-
tine that is then used in the synthesis of GSH, an anti-oxidant
that restores the intracellular redox balance and protects cells
from death induced by reactive oxygen species (ROS) or reactive
nitrogen species (RNS; Bannai, 1986). As an adaptive response,
xCT is upregulated when intracellular levels of GSH are low,
such as in settings of oxidative stress among late stage HIV-AIDS
patients who are also likely to experience more aggressive KS
(Mallery et al., 2004; Ma et al., 2009, 2013). Accordingly, we found
that xCT is upregulated within more advanced KS lesions that
also express high levels of the KSHV latency-associated nuclear
antigen (LANA) compared to early-stage KS lesions (Qin et al.,
2010b). In the same study, we found that KSHV encodes multiple
microRNAs that directly target BACH-1, a negative transcrip-
tional regulator of xCT that binds to the cis-acting “Antioxidant
Response Element” (ARE) within the xCT promoter region,
thereby upregulating the receptor, which in turn facilitates viral
dissemination and enhanced survival of virus-infected cells in the
host microenvironment (Qin et al., 2010b). Our findings of a
role for KSHV in regulation of its own receptor were the first to
demonstrate a direct link between xCT receptor usage and KSHV
pathogenesis, and have inspired ongoing work aimed at defining
post-entry interactions of KSHV with the human host that can be
explored as viable therapeutic targets for clinical management of
KS and other virus-associated cancers.
By virtue of its role in maintaining the intracellular redox bal-
ance, xCT also protects KSHV-infected cells from death induced
by RNS and other insults. Indeed, RNAi silencing of xCT expres-
sion impairs the resistance of KSHV-infected mouse macrophage
RAW cells to death induced by the nitric oxide (NO) donor, S-
nitroso-N-acetylpenicillamine (SNAP; Qin et al., 2010b). We and
others also recently reported that overexpression of xCT induces
upregulation of 14-3-3β (a downstream regulatory protein from
KSHV-infected cells and KS lesions), resulting in intracellular
signal transduction via MAPK and increased cytokine release, cell
growth, and invasiveness (Zeng et al., 2010; Qin et al., 2013).
By enhancing biosynthesis of intracellular GSH, xCT also pro-
tects cancer cells from drug-induced oxidative stress by mediat-
ing detoxification and extrusion of chemotherapeutic drugs via
its biophysical interactions with multidrug resistance proteins
(Haimeur et al., 2002; Okuno et al., 2003; Filipits et al., 2005; Yang
et al., 2006). For example, GSH induces a conformational change
in the multidrug resistance-associated protein-1 (MRP1), which
impairs its interaction with one of the most commonly used
chemotherapeutic drugs, doxorubicin, and consequently reduces
its drug-efflux function (Manciu et al., 2003).
Interestingly, the xCT/CD98 cystine transporter tightly asso-
ciates with a multi-molecular “supercomplex” on the cell-surface
that also includes Emmprin (CD147), LYVE-1 (a hyaluronan
receptor), and BCRP (a drug-efflux pump protein responsible
for multidrug resistance of KSHV-infected PEL cells; Qin et al.,
2011). Within this complex, Emmprin has been reported to confer
resistance to some chemotherapeutic drugs (Okuno et al., 2003;
Yang et al., 2007; Zou et al., 2007). Indeed, expression of xCT
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in a panel of cancer cell lines has been associated with potency
of 1,400 candidate anticancer drugs, including cisplatin (Huang
et al., 2005). Since KSHV induces expression of both xCT and
Emmprin in a variety of infected cell lines including PEL cells
(Qin et al., 2010a,b; Dai et al., 2012, 2014a), it is probable
that stabilization of the xCT/CD98/CD147 supercomplex plays
a critical role not only in intracellular energy metabolism (Xu
and Hemler, 2005) but also in potentiating the efflux functions of
multidrug transporters, which could enhance survival of KSHV-
associated cancers including PEL.
xCT AS A THERAPEUTIC TARGET FOR KSHV-ASSOCIATED LYMPHOMA
As mentioned above, KSHV is a principal causative agent of PEL,
which comprises transformed B cells harboring viral episomes.
PEL is a rapidly progressing malignancy that arises preferentially
within the pleural or peritoneal cavities of patients infected with
HIV (Cesarman et al., 1995), with a median survival time of
approximately 6 months even under conventional chemotherapy
(Chen et al., 2007). xCT is highly expressed in a variety of
KSHV-infected PEL cell-lines, and targeting xCT by either RNAi
or selective inhibitors induces significant cell apoptosis poten-
tially through regulation of host and viral factors including: (i)
reducing intracellular GSH, (ii) increasing ROS, (iii) repressing
cell-proliferation-related signaling, and (iv) inducing viral lytic
gene expression (Dai et al., 2014a). We also demonstrated that
an xCT selective inhibitor, Sulfasalazine (SASP), which has been
approved by FDA for treatment of some inflammatory diseases
(Gout et al., 2001), can effectively prevent PEL tumor progres-
sion in an immune-deficient xenograft mouse model (Dai et al.,
2014a,c), supporting the potential benefit of targeting xCT as a
strategy for attenuating progression to overt lymphomagenesis.
With this as an important goal, additional studies are warranted
in order to identify other cell-proliferation/growth-related factors
that could be impacted by selective targeting of xCT (including
those involved in cell-cycle and autophagy) not only within PEL
cells but also in Burkitt’s lymphoma (BL)-derived cell lines where
xCT is also highly expressed (Dai et al., 2014a).
xCT AND HIV PATHOGENESIS
It has been reported that the HIV-encoded transactivator pro-
tein Tat can upregulate xCT expression within human primary
microglia, retinal pigment epithelium and in retina from Tat-
transgenic mice (Bridges et al., 2004; Gupta et al., 2010; Pang
et al., 2013), although the underlying mechanisms remain largely
unknown. Increased expression of xCT within ocular tissue
results in increased release of excitotoxic glutamate in exchange
for extracellular cystine, which contributes to the excitotoxicity
associated with non-infectious AIDS retinopathy (Bridges et al.,
2004; Gupta et al., 2010). In this respect, the direct link between
the amino acid transport activity of xCT and retinopathy among
HIV-infected individuals suggests that targeting xCT may rep-
resent a promising new strategy for ameliorating this disease in
high-risk groups (Bridges et al., 2004; Butler and Thorne, 2012).
xCT AND BACTERIAL INFECTION
The xCT-anchored xc− cystine/glutamate transporter plays an
important role not only in viral pathogenesis but also during
bacterial infection. Thus, xCT mRNA and the cystine/glutamate
transporter activity are dramatically induced in mouse peri-
toneal macrophages in vitro by bacterial lipopolysaccharide (LPS)
even at very low concentrations, similar to that observed in the
plasma of patients with sepsis (Sato et al., 1995). The same
group further confirmed that ambient oxygen tension and/or
oxidative stress are required for LPS-induced xCT expression and
cystine/glutamate transport in mouse peritoneal macrophages in
vitro (Sato et al., 2001). In an experimental endotoxemia mouse
model, xCT mRNA was constitutively expressed in the brain,
thymus, and spleen, and xCT mRNA was strongly upregulated in
thymus and spleen following administration of a sublethal dose
of LPS, indicating that xCT plays an important role during the
host inflammatory response to bacterial infection in vivo (Taguchi
et al., 2007). Interestingly, LPS induction of xCT expression is not
mediated by the ARE in the promoter region as described previ-
ously (Sasaki et al., 2002); as such, the underlying mechanism for
LPS-induced xCT expression requires further investigation.
CONCLUDING REMARKS
In contrast to extensive studies of the role of xCT as an amino-acid
transporter involved in the survival of normal and cancer cells,
there are very limited data describing its role in microbial infec-
tion and/or the pathogenesis of associated diseases. According to
current data, at least 16.1% of cancers worldwide are linked to
infectious diseases, and in Sub-Saharan Africa, this rate is almost
32.7% (de Martel et al., 2012). Nonetheless, we note that although
the preponderance of infectious cancer is associated with viruses,
Helicobacter pylori, Mycobacterium, and some parasites have also
been associated with a direct or potentiating role in development
of some cancers as well (Fried et al., 2011; Pallis and Syrigos, 2013;
Mesri et al., 2014; Park et al., 2014). In many cases, studies of
the molecular mechanisms by which these infections contribute
to the defining markers of cancer initiation and progression
have yielded important insights into strategies for control and
prevention of infectious disease. More specifically, recent findings
from our group and others about the role of xCT in the patho-
genesis of KSHV (a model oncogenic virus) have revealed the
multi-functional role of xCT not only during primary infection
but also in post-entry events that promote infected cell survival
and tumorigenesis. Moreover, additional data demonstrating the
biologic function of xCT in HIV and bacterial infection further
illustrate the broad regulatory role of this protein in various
infectious diseases. Therefore, to better understand the breadth of
the xCT functional “network”, it will be essential to elucidate: (i)
the factors that regulate its expression in various cell types, (ii)
the cognate proteins that interact with xCT on cell membrane
in response to engagement by exogenous pathogens, (iii) the
downstream genes that are controlled by signals initiated by these
interactions at the cell surface, and (iv) whether xCT expression
in tumors correlates with disease progression and resistance to
chemotherapy in cancer-bearing individuals. New information
derived from these studies will guide approaches for clinical man-
agement of xCT-associated abnormalities, including the develop-
ment of more specific pharmacological methods for inhibiting
or inducing system xc− activity as a means for modulating pro-
gression of associated disease. With respect to PEL, cell-culture
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systems such as Nb2-SFJCD1 lymphoma cells (Gout et al., 2001)
could be used as platforms for screening small molecule lead-
compound libraries for novel xCT inhibitors. Along these lines,
it is worth noting that some xCT inhibitors such as SASP have
already been approved by FDA for treatment of certain infectious
diseases, and its anti-cancer effects are being evaluated in clinical
trials (Gout et al., 2001; Robe et al., 2006; Sontheimer and Bridges,
2012).
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